These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

639 related articles for article (PubMed ID: 1319456)

  • 1. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies.
    Murray RJ; Kurilla MG; Brooks JM; Thomas WA; Rowe M; Kieff E; Rickinson AB
    J Exp Med; 1992 Jul; 176(1):157-68. PubMed ID: 1319456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development.
    Khanna R; Burrows SR; Kurilla MG; Jacob CA; Misko IS; Sculley TB; Kieff E; Moss DJ
    J Exp Med; 1992 Jul; 176(1):169-76. PubMed ID: 1377222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human cytotoxic T-cell responses against Epstein-Barr virus nuclear antigens demonstrated by using recombinant vaccinia viruses.
    Murray RJ; Kurilla MG; Griffin HM; Brooks JM; Mackett M; Arrand JR; Rowe M; Burrows SR; Moss DJ; Kieff E
    Proc Natl Acad Sci U S A; 1990 Apr; 87(8):2906-10. PubMed ID: 2158098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T cell recognition of Epstein-Barr virus associated lymphomas.
    Rickinson AB; Murray RJ; Brooks J; Griffin H; Moss DJ; Masucci MG
    Cancer Surv; 1992; 13():53-80. PubMed ID: 1330300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11-restricted cytotoxic T lymphocytes: implications for down-regulation of HLA-A11 in Burkitt lymphoma.
    Gavioli R; De Campos-Lima PO; Kurilla MG; Kieff E; Klein G; Masucci MG
    Proc Natl Acad Sci U S A; 1992 Jul; 89(13):5862-6. PubMed ID: 1321426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus-specific cytotoxic T-cell recognition of transfectants expressing the virus-coded latent membrane protein LMP.
    Murray RJ; Wang D; Young LS; Wang F; Rowe M; Kieff E; Rickinson AB
    J Virol; 1988 Oct; 62(10):3747-55. PubMed ID: 2843672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised.
    Hill AB; Lee SP; Haurum JS; Murray N; Yao QY; Rowe M; Signoret N; Rickinson AB; McMichael AJ
    J Exp Med; 1995 Jun; 181(6):2221-8. PubMed ID: 7539044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune escape by Epstein-Barr virus (EBV) carrying Burkitt's lymphoma: in vitro reconstitution of sensitivity to EBV-specific cytotoxic T cells.
    Masucci MG; Zhang QJ; Gavioli R; De Campos-Lima PO; Murray RJ; Brooks J; Griffin H; Ploegh H; Rickinson AB
    Int Immunol; 1992 Nov; 4(11):1283-92. PubMed ID: 1282031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide.
    Brooks JM; Murray RJ; Thomas WA; Kurilla MG; Rickinson AB
    J Exp Med; 1993 Sep; 178(3):879-87. PubMed ID: 7688791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Major histocompatibility complex class I-restricted cytotoxic T lymphocyte responses to Epstein-Barr virus in children.
    Tamaki H; Beaulieu BL; Somasundaran M; Sullivan JL
    J Infect Dis; 1995 Sep; 172(3):739-46. PubMed ID: 7658067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes.
    Khanna R; Burrows SR; Nicholls J; Poulsen LM
    Eur J Immunol; 1998 Feb; 28(2):451-8. PubMed ID: 9521052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A recombinant adenovirus expressing an Epstein-Barr virus (EBV) target antigen can selectively reactivate rare components of EBV cytotoxic T-lymphocyte memory in vitro.
    Morgan SM; Wilkinson GW; Floettmann E; Blake N; Rickinson AB
    J Virol; 1996 Apr; 70(4):2394-402. PubMed ID: 8642667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
    Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
    Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr virus-infected B cells of males with the X-linked lymphoproliferative syndrome stimulate and are susceptible to T-cell-mediated lysis.
    Jäger M; Benninger-Döring G; Prang N; Sylla BS; Laumbacher B; Wank R; Wolf H; Schwarzmann F
    Int J Cancer; 1998 May; 76(5):694-701. PubMed ID: 9610728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2.
    Lee SP; Thomas WA; Murray RJ; Khanim F; Kaur S; Young LS; Rowe M; Kurilla M; Rickinson AB
    J Virol; 1993 Dec; 67(12):7428-35. PubMed ID: 7693972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance.
    Khanna R; Burrows SR; Steigerwald-Mullen PM; Thomson SA; Kurilla MG; Moss DJ
    Virology; 1995 Dec; 214(2):633-7. PubMed ID: 8553567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of Epstein-Barr virus nuclear antigens in anti-IgM-stimulated B cells following recombinant vaccinia infection and their recognition by human cytotoxic T cells.
    Khanna R; Jacob CA; Burrows SR; Kurilla MG; Kieff E; Misko IS; Sculley TB; Moss DJ
    Immunology; 1991 Nov; 74(3):504-10. PubMed ID: 1722774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs.
    Gottschalk S; Ng CY; Perez M; Smith CA; Sample C; Brenner MK; Heslop HE; Rooney CM
    Blood; 2001 Feb; 97(4):835-43. PubMed ID: 11159505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection.
    Rickinson AB; Moss DJ
    Annu Rev Immunol; 1997; 15():405-31. PubMed ID: 9143694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The life span of major histocompatibility complex-peptide complexes influences the efficiency of presentation and immunogenicity of two class I-restricted cytotoxic T lymphocyte epitopes in the Epstein-Barr virus nuclear antigen 4.
    Levitsky V; Zhang QJ; Levitskaya J; Masucci MG
    J Exp Med; 1996 Mar; 183(3):915-26. PubMed ID: 8642295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.